TY - JOUR
T1 - The feasibility of the PAM intervention to support treatment-adherence in people with hypertension in primary care
T2 - a randomised clinical controlled trial
AU - Kassavou, Aikaterini
AU - Mirzaei, Venus
AU - Shpendi, Sonia
AU - Brimicombe, James
AU - Chauhan, Jagmohan
AU - Bhattacharya, Debi
AU - Naughton, Felix
AU - Hardeman, Wendy
AU - Eborall, Helen
AU - Van Emmenis, Miranda
AU - De Simoni, Anna
AU - Takhar, Amrit
AU - Gupta, Pankaj
AU - Patel, Prashanth
AU - Mascolo, Cecilia
AU - Prevost, Andrew Toby
AU - Morris, Stephen
AU - Griffin, Simon
AU - McManus, Richard J.
AU - Mant, Jonathan
AU - Sutton, Stephen
N1 - Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2021/4/26
Y1 - 2021/4/26
N2 - The PAM intervention is a behavioural intervention to support adherence to anti-hypertensive medications and therefore to lower blood pressure. This feasibility trial recruited 101 nonadherent patients (54% male, mean age 65.8 years) with hypertension and high blood pressure from nine general practices in the UK. The trial had 15.5% uptake and 7.9% attrition rate. Patients were randomly allocated to two groups: the intervention group (n = 61) received the PAM intervention as an adjunct to usual care; the control group (n = 40) received usual care only. At 3 months, biochemically validated medication adherence was improved by 20% (95% CI 3-36%) in the intervention than control, and systolic blood pressure was reduced by 9.16 mmHg (95% CI 5.69-12.64) in intervention than control. Improvements in medication adherence and reductions in blood pressure suggested potential intervention effectiveness. For a subsample of patients, improvements in medication adherence and reductions in full lipid profile (cholesterol 1.39 mmol/mol 95% CI 0.64-1.40) and in glycated haemoglobin (3.08 mmol/mol, 95% CI 0.42-5.73) favoured the intervention. A larger trial will obtain rigorous evidence about the potential clinical effectiveness and cost-effectiveness of the intervention.Trial registration Trial date of first registration 28/01/2019. ISRCTN74504989. https://doi.org/10.1186/ISRCTN74504989 .
AB - The PAM intervention is a behavioural intervention to support adherence to anti-hypertensive medications and therefore to lower blood pressure. This feasibility trial recruited 101 nonadherent patients (54% male, mean age 65.8 years) with hypertension and high blood pressure from nine general practices in the UK. The trial had 15.5% uptake and 7.9% attrition rate. Patients were randomly allocated to two groups: the intervention group (n = 61) received the PAM intervention as an adjunct to usual care; the control group (n = 40) received usual care only. At 3 months, biochemically validated medication adherence was improved by 20% (95% CI 3-36%) in the intervention than control, and systolic blood pressure was reduced by 9.16 mmHg (95% CI 5.69-12.64) in intervention than control. Improvements in medication adherence and reductions in blood pressure suggested potential intervention effectiveness. For a subsample of patients, improvements in medication adherence and reductions in full lipid profile (cholesterol 1.39 mmol/mol 95% CI 0.64-1.40) and in glycated haemoglobin (3.08 mmol/mol, 95% CI 0.42-5.73) favoured the intervention. A larger trial will obtain rigorous evidence about the potential clinical effectiveness and cost-effectiveness of the intervention.Trial registration Trial date of first registration 28/01/2019. ISRCTN74504989. https://doi.org/10.1186/ISRCTN74504989 .
UR - http://www.scopus.com/inward/record.url?scp=85106087304&partnerID=8YFLogxK
U2 - 10.1038/s41598-021-88170-2
DO - 10.1038/s41598-021-88170-2
M3 - Article
C2 - 33903656
AN - SCOPUS:85106087304
SN - 2045-2322
VL - 11
SP - 8897
JO - Scientific Reports
JF - Scientific Reports
IS - 1
ER -